15 New Messages
Digest #19613
Messages
Tue Apr 2, 2013 9:57 pm (PDT) . Posted by:
"Inta" intamaesarinta
Dear mba Julia,
Dulu saya pake 3 days rule. Ini berlangsung sampai anak anak saya setahun, gak semua makanan sih terutama yang kira kira memicu alergi aja karena saya dan suami punya food allergy.
Selain itu buat liat preferensi anak saya juga terhadap bahan makanan yang lagi dicoba. Kalau menurut saya sih gak bosen yah, kan bisa di kombinasi sama yang udah lulus uji coba.
Mba Nana,
Kalau saya pakai panduannya WHO, gak ada larangan makanan tertentu dan batasan umur kecuali yah itu tadi makanan dengan resiko alergi tingi seperti, telur, seafood, kacang kacangan, beri beri an. Panduannya ada dimana, cek arsip milis yaah udah sering banget berkeliaran soalnya. Atau gugling aja dengan keyword participant material UNICEF.
Untuk 7m bisa dikenalin labu2an, umbi2an, bayam, kangkung, wortel, brokoli apa aja, bumbu dapur kayak bawang, daun salam, daun bawang,. jangan lupa daging merahnya yah mba, udah bisa kenalan dari 6.5m loh.
Cheers, Inta
Dulu saya pake 3 days rule. Ini berlangsung sampai anak anak saya setahun, gak semua makanan sih terutama yang kira kira memicu alergi aja karena saya dan suami punya food allergy.
Selain itu buat liat preferensi anak saya juga terhadap bahan makanan yang lagi dicoba. Kalau menurut saya sih gak bosen yah, kan bisa di kombinasi sama yang udah lulus uji coba.
Mba Nana,
Kalau saya pakai panduannya WHO, gak ada larangan makanan tertentu dan batasan umur kecuali yah itu tadi makanan dengan resiko alergi tingi seperti, telur, seafood, kacang kacangan, beri beri an. Panduannya ada dimana, cek arsip milis yaah udah sering banget berkeliaran soalnya. Atau gugling aja dengan keyword participant material UNICEF.
Untuk 7m bisa dikenalin labu2an, umbi2an, bayam, kangkung, wortel, brokoli apa aja, bumbu dapur kayak bawang, daun salam, daun bawang,. jangan lupa daging merahnya yah mba, udah bisa kenalan dari 6.5m loh.
Cheers, Inta
Tue Apr 2, 2013 10:53 pm (PDT) . Posted by:
ariana_tirtasari
Dear Mom Putri,
Wahhh bole di coba.. :D tapi biasanya diapain ya red meat diapain ya? any recommended link? :)
Saya sih mau-mau aja kasi ke baby.. Tp biasa ortu yang msh larang kasi ini itu, takut kenapa2 sama baby nya.. Kadang dilema jg.. Tp banyak nekad nya :D haha
Thanks,
Regards,
Nana
Sent from my BlackBerry0…3 smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Wahhh bole di coba.. :D tapi biasanya diapain ya red meat diapain ya? any recommended link? :)
Saya sih mau-mau aja kasi ke baby.. Tp biasa ortu yang msh larang kasi ini itu, takut kenapa2 sama baby nya.. Kadang dilema jg.. Tp banyak nekad nya :D haha
Thanks,
Regards,
Nana
Sent from my BlackBerry0…3 smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Tue Apr 2, 2013 10:55 pm (PDT) . Posted by:
ariana_tirtasari
Mba Inta,
Terima kasih buat comment nya :)
Ntar saya coba googling ttg WHO jg liat file milis terdahulu. Maklum newbie..
Labu/kabocha uda dicobain jg jadiin puree.. Lancar jaya.. Cm kl kabocha mmg bikin gk BAB ya?! Jd sy bantu dngn puree pear, yg penting tiap hari BAB aja..
Ada yang tau link ttg menu-menu mkannya juga gk ya.. Biar bisa nambah referensi..
thanks for sharing :)
Regards,
Nana
Sent from my BlackBerry0…3 smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Terima kasih buat comment nya :)
Ntar saya coba googling ttg WHO jg liat file milis terdahulu. Maklum newbie..
Labu/kabocha uda dicobain jg jadiin puree.. Lancar jaya.. Cm kl kabocha mmg bikin gk BAB ya?! Jd sy bantu dngn puree pear, yg penting tiap hari BAB aja..
Ada yang tau link ttg menu-menu mkannya juga gk ya.. Biar bisa nambah referensi..
thanks for sharing :)
Regards,
Nana
Sent from my BlackBerry0…3 smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Tue Apr 2, 2013 10:41 pm (PDT) . Posted by:
"safira syfa" safira.syfa
Selamat siang,
Adakah yang pernah operasi gigi geraham belakang di RS.mitra keluarga
bekasi barat dengan Drg.Ronny Corputty?Biayanya berapa ya??
Terima kasih
Lilis
[Non-text portions of this message have been removed]
Adakah yang pernah operasi gigi geraham belakang di RS.mitra keluarga
bekasi barat dengan Drg.Ronny Corputty?Biayanya berapa ya??
Terima kasih
Lilis
[Non-text portions of this message have been removed]
Wed Apr 3, 2013 12:32 am (PDT) . Posted by:
amianakbinus
Alo mba lilis
Ditelp saja rsnya, tnykan harganya.
Atau dtg lgsg k rs nya.
-ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Ditelp saja rsnya, tnykan harganya.
Atau dtg lgsg k rs nya.
-ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Tue Apr 2, 2013 11:12 pm (PDT) . Posted by:
"/Ghozan"
lanjutan....
bravo india....
Analysis: Big Pharma down, not out, after Indian patent blow
By Ben Hirschler and Kaustubh Kulkarni
LONDON/MUMBAI | Tue Apr 2, 2013 3:53pm EDT
(Reuters) - Stung by a landmark patent defeat, Western drugmakers will
be wary about launching new products in India, but they cannot afford to
quit a country tipped to be the world's eighth largest market for
medicines by 2016.
Makers of patented drugs will in future have to get more creative about
doing business in India, including striking deals with local firms to
sell cheaper versions of their drugs, industry experts believe.
The decision by India's Supreme Court on Monday not to allow a patent on
Novartis AG's cancer drug Glivec angered but did not surprise U.S. and
European drug companies, given past intellectual property (IP) setbacks.
And it is unlikely to send them rushing for the exit.
"India is too big to ignore," said Amit Backliwal, who heads South Asian
operations for leading healthcare information provider IMS Health.
"Companies will definitely get cautious, and it definitely means a
change in their business model, but I don't think they will pull out."
On paper, there is huge potential in India's rapidly growing $13
billion-a-year drugs market, which is driven these days by chronic
diseases such as diabetes as well as infections.
So far, though, it has failed to become a money-spinner for the world's
top pharmaceutical companies, despite a new law in 2005 allowing drug
patents for the first time.
Innovative patented drugs make up no more than 5 percent of sales,
according to IMS, and they have been under siege after a series of
rulings allowing generics firms to over-ride patents for cancer drugs
like Bayer AG's Nexavar.
New Delhi has pulled no punches in its fight with Big Pharma, both by
raising the bar for patents and being ready to issue so-called
compulsory licenses that open the door for cheap generics when patented
drugs are deemed unaffordable.
In the face of such hurdles, some companies are already building new
business models.
Roche Holding, for example, plans to offer cut-price versions of two
blockbuster cancer drugs Herceptin and MabThera under an alliance with
Indian generics firm Emcure Pharmaceuticals.
It is a scheme that Ajay Kumar Sharma, associate director of the
pharmaceutical and biotech practice at business consultancy Frost &
Sullivan, believes other drugmakers could now emulate.
CALCULATED RISK
India's stance on IP has long been a thorn in the side of Western
business, prompting calls by Pfizer Inc and other U.S. firms last month
for more pressure on the country to reform policies that can block U.S.
exports.
The argument cuts little ice in India, where officials see differential
pricing - steep discounts for less well-off markets - as an obvious
option for Western companies.
"It is up to them to decide on India. Don't forget, India is a large
market, a country of 1.2 billion," said Raghunath Mashelkar, former
director general of the Council for Scientific and Industrial Research
and an architect of India's IP policies.
With differential pricing common in industries from autos to mobile
phones, he argues pharmaceutical firms must find new ways to make
products affordable for lower-income groups.
"Drugmakers will have to work out strategies for the lower sections, to
give affordable access to medicines and make money by large volumes and
smaller margins," he told Reuters. "And then they will look at the
middle and the upper sections and make money through smaller volumes but
higher margins."
It is a calculated risk, yet a number of drugmakers are already coming
around to the view that trading volume for price is the way forward.
One of those is GlaxoSmithKline Plc, which has a large footprint in
India and has just invested $900 million to raise its stake in its
consumer healthcare subsidiary.
GSK's diversified approach to healthcare is shared by a number of
rivals, including Novartis, that also have big interests in
over-the-counter (OTC) remedies and branded generics, in addition to
innovative medicines.
It is this non-prescription sector that is set to dominate in India,
driving double-digit percentage growth in a market that IMS has forecast
will reach $24-34 billion by 2016, vaulting the country to eighth from
14th in the global league table.
PricewaterhouseCoopers puts sales by 2020 at $49 billion.
Much of the new business will still come from cheap generics made by
local companies, but Western firms are also seeking to put their brands
on unpatented medicines, prompting the likes of Abbott Laboratories and
Daiichi Sankyo Co Ltd to buy up Indian companies.
BETTER BETS ELSEWHERE
With sales of patented drugs in Western countries slowing, emerging
markets are a vital growth driver for drugmakers. India cannot be
ignored, but there are clearly better bets elsewhere.
"Emerging markets are growing at two to three times the rate of Western
markets, but you've got to be in the right markets - you want to be in
China and in Brazil," said Tim Race at Deutsche Bank.
"India could be a really exciting market, given its increasing middle
class, but the home-grown generics industry is extremely strong, and the
patent situation is very difficult."
India's patent stance also reverberates beyond its shores, since the
country's generics firms export their cheap medicines across the
developing world.
So far, no other country has followed India with similar laws preventing
the kind of secondary patent that stymied Glivec, though Michelle
Childs, head of drug access policy at Medecins Sans Frontieres, said
others were raising the patent bar in more subtle ways.
Argentina, for example, recently issued guidelines to patent examiners
urging stricter rules for granting new patents, and other countries have
used compulsory licenses, she noted.
"It's putting pressure on pharmaceutical companies to realise they can't
continue to charge prices which are unaffordable to the majority of
people," Childs said.
(Additional reporting by Caroline Copley in Zurich; Editing by Will
Waterman)
http://www.reuters.com/article/2013/04/02/us-india-pharmaceuticals-idUSBRE9310K420130402
bravo india....
Analysis: Big Pharma down, not out, after Indian patent blow
By Ben Hirschler and Kaustubh Kulkarni
LONDON/MUMBAI | Tue Apr 2, 2013 3:53pm EDT
(Reuters) - Stung by a landmark patent defeat, Western drugmakers will
be wary about launching new products in India, but they cannot afford to
quit a country tipped to be the world's eighth largest market for
medicines by 2016.
Makers of patented drugs will in future have to get more creative about
doing business in India, including striking deals with local firms to
sell cheaper versions of their drugs, industry experts believe.
The decision by India's Supreme Court on Monday not to allow a patent on
Novartis AG's cancer drug Glivec angered but did not surprise U.S. and
European drug companies, given past intellectual property (IP) setbacks.
And it is unlikely to send them rushing for the exit.
"India is too big to ignore," said Amit Backliwal, who heads South Asian
operations for leading healthcare information provider IMS Health.
"Companies will definitely get cautious, and it definitely means a
change in their business model, but I don't think they will pull out."
On paper, there is huge potential in India's rapidly growing $13
billion-a-year drugs market, which is driven these days by chronic
diseases such as diabetes as well as infections.
So far, though, it has failed to become a money-spinner for the world's
top pharmaceutical companies, despite a new law in 2005 allowing drug
patents for the first time.
Innovative patented drugs make up no more than 5 percent of sales,
according to IMS, and they have been under siege after a series of
rulings allowing generics firms to over-ride patents for cancer drugs
like Bayer AG's Nexavar.
New Delhi has pulled no punches in its fight with Big Pharma, both by
raising the bar for patents and being ready to issue so-called
compulsory licenses that open the door for cheap generics when patented
drugs are deemed unaffordable.
In the face of such hurdles, some companies are already building new
business models.
Roche Holding, for example, plans to offer cut-price versions of two
blockbuster cancer drugs Herceptin and MabThera under an alliance with
Indian generics firm Emcure Pharmaceuticals.
It is a scheme that Ajay Kumar Sharma, associate director of the
pharmaceutical and biotech practice at business consultancy Frost &
Sullivan, believes other drugmakers could now emulate.
CALCULATED RISK
India's stance on IP has long been a thorn in the side of Western
business, prompting calls by Pfizer Inc and other U.S. firms last month
for more pressure on the country to reform policies that can block U.S.
exports.
The argument cuts little ice in India, where officials see differential
pricing - steep discounts for less well-off markets - as an obvious
option for Western companies.
"It is up to them to decide on India. Don't forget, India is a large
market, a country of 1.2 billion," said Raghunath Mashelkar, former
director general of the Council for Scientific and Industrial Research
and an architect of India's IP policies.
With differential pricing common in industries from autos to mobile
phones, he argues pharmaceutical firms must find new ways to make
products affordable for lower-income groups.
"Drugmakers will have to work out strategies for the lower sections, to
give affordable access to medicines and make money by large volumes and
smaller margins," he told Reuters. "And then they will look at the
middle and the upper sections and make money through smaller volumes but
higher margins."
It is a calculated risk, yet a number of drugmakers are already coming
around to the view that trading volume for price is the way forward.
One of those is GlaxoSmithKline Plc, which has a large footprint in
India and has just invested $900 million to raise its stake in its
consumer healthcare subsidiary.
GSK's diversified approach to healthcare is shared by a number of
rivals, including Novartis, that also have big interests in
over-the-counter (OTC) remedies and branded generics, in addition to
innovative medicines.
It is this non-prescription sector that is set to dominate in India,
driving double-digit percentage growth in a market that IMS has forecast
will reach $24-34 billion by 2016, vaulting the country to eighth from
14th in the global league table.
PricewaterhouseCoop
Much of the new business will still come from cheap generics made by
local companies, but Western firms are also seeking to put their brands
on unpatented medicines, prompting the likes of Abbott Laboratories and
Daiichi Sankyo Co Ltd to buy up Indian companies.
BETTER BETS ELSEWHERE
With sales of patented drugs in Western countries slowing, emerging
markets are a vital growth driver for drugmakers. India cannot be
ignored, but there are clearly better bets elsewhere.
"Emerging markets are growing at two to three times the rate of Western
markets, but you've got to be in the right markets - you want to be in
China and in Brazil," said Tim Race at Deutsche Bank.
"India could be a really exciting market, given its increasing middle
class, but the home-grown generics industry is extremely strong, and the
patent situation is very difficult."
India's patent stance also reverberates beyond its shores, since the
country'
developing world.
So far, no other country has followed India with similar laws preventing
the kind of secondary patent that stymied Glivec, though Michelle
Childs, head of drug access policy at Medecins Sans Frontieres, said
others were raising the patent bar in more subtle ways.
Argentina, for example, recently issued guidelines to patent examiners
urging stricter rules for granting new patents, and other countries have
used compulsory licenses, she noted.
"It'
continue to charge prices which are unaffordable to the majority of
people," Childs said.
(Additional reporting by Caroline Copley in Zurich; Editing by Will
Waterman)
http://www.reuters.
Tue Apr 2, 2013 11:56 pm (PDT) . Posted by:
"Niken Choirunnisa" niken_luv
Dear Mom's
Anakku umur 9bulan, skrg lagi sariawan dibibir sm dilidah, gmn ya moms cara menyembuhkannya dan apa obatnya klo ada.
Mksh,
Niken Bundanya Fathan & Quinna
[Non-text portions of this message have been removed]
Anakku umur 9bulan, skrg lagi sariawan dibibir sm dilidah, gmn ya moms cara menyembuhkannya dan apa obatnya klo ada.
Mksh,
Niken Bundanya Fathan & Quinna
[Non-text portions of this message have been removed]
Wed Apr 3, 2013 12:03 am (PDT) . Posted by:
amianakbinus
Alo mba niken
ksh buah dingin, jus buah, kemut2 es, ato es krim , utk menyamankan.
Ga alergi es kan?
-ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
ksh buah dingin, jus buah, kemut2 es, ato es krim , utk menyamankan.
Ga alergi es kan?
-ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Wed Apr 3, 2013 12:06 am (PDT) . Posted by:
"Imel" maxine_id
Mbak ami,
Mau tanya kalau kasih kenalog boleh ga ya?
Salam hangat
Mau tanya kalau kasih kenalog boleh ga ya?
Salam hangat
Wed Apr 3, 2013 12:31 am (PDT) . Posted by:
amianakbinus
Alo mba Imel
Kalau baca mengenai stomatitis aphthou, (sy buka wikipedia inggris, medscape.com) ada treatment pemberian orobase combined topical steroid (triamcinolone "kenalog") to reduce pain.
tapi sbtlnya kalau dibaca lgkp referensi2nya, kondisi ini kan tdk berbahaya, jd kalau bs dinyamankan dgn tdk mgunakan obat2an lebih baik lg. Toh mmg tdk menyembuhkan jg obat2annya, hny mengurangi skt. Kalau sy memilih utk memberikan es krim, es buah serut.
Cmiiw all,
Ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Kalau baca mengenai stomatitis aphthou, (sy buka wikipedia inggris, medscape.com) ada treatment pemberian orobase combined topical steroid (triamcinolone "kenalog"
tapi sbtlnya kalau dibaca lgkp referensi2nya, kondisi ini kan tdk berbahaya, jd kalau bs dinyamankan dgn tdk mgunakan obat2an lebih baik lg. Toh mmg tdk menyembuhkan jg obat2annya, hny mengurangi skt. Kalau sy memilih utk memberikan es krim, es buah serut.
Cmiiw all,
Ami
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Dear Mba Niken,
Salam kenal ya, buat smuanya juga yaa..newbie soalnya..:)
Baby ku juga pernah tu sariwan, wktu itu diresepin candistin sama kenalog ma dsanya.
Cepet ilang tu sariwannya.
Regards,
Selly
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...!
Salam kenal ya, buat smuanya juga yaa..newbie soalnya..:)
Baby ku juga pernah tu sariwan, wktu itu diresepin candistin sama kenalog ma dsanya.
Cepet ilang tu sariwannya.
Regards,
Selly
Sent from my BlackBerry® smartphone from Sinyal Bagus XL, Nyambung Teruuusss...
Wed Apr 3, 2013 12:41 am (PDT) . Posted by:
"Imel" maxine_id
Æ Í¡Ì´Ì´Ì´Ì´Ì´Ì´.Ì®Æ Í¡Ì´(y)
<' si . si . si 
îš™^îš™ mbak. Tarengkiuw.
Salam hangat
<' si . si . si 
îš™^îš™ mbak. Tarengkiuw.
Salam hangat
Wed Apr 3, 2013 12:07 am (PDT) . Posted by:
"safira syfa" safira.syfa
Selamat siang dok,
Bayi saya 6bulan, sering sekali menggaruk kepala dan telingga hingga kadang
terluka.Apakah hal ini wajar?Padahal kalau mandi, kepala dan telingganya
selalu saya bersihkan.
Terima kasih
Lilis
[Non-text portions of this message have been removed]
Bayi saya 6bulan, sering sekali menggaruk kepala dan telingga hingga kadang
terluka.Apakah hal ini wajar?Padahal kalau mandi, kepala dan telingganya
selalu saya bersihkan.
Terima kasih
Lilis
[Non-text portions of this message have been removed]
Wed Apr 3, 2013 12:38 am (PDT) . Posted by:
"Laura Rondo" laura_stefanie
Mo ikutan nimbrung...
Dari film doc mcstuffin, anakku Tim (27bl) belajar ttg stetoskop, ternyata untuk dengerin dug2 di dada katanya (suara jantung)
Tiap papanya pulang, dia suka nyambut "papa periksa dulu" » mestinya papa cuci tangan dulu yaaaaah..
Dan... dan...
Dia ga kuatir sama yg namanya dokter.
Dan, mamanya selalu diingatin, ttg mencari diagnosa, krn disitu pun diagnosa ditegakkan setelah si anak ngeliat ciri2 fisik pasiennya..baru ke treatment.
Regards
Laura
Dari film doc mcstuffin, anakku Tim (27bl) belajar ttg stetoskop, ternyata untuk dengerin dug2 di dada katanya (suara jantung)
Tiap papanya pulang, dia suka nyambut "papa periksa dulu" » mestinya papa cuci tangan dulu yaaaaah..
Dan... dan...
Dia ga kuatir sama yg namanya dokter.
Dan, mamanya selalu diingatin, ttg mencari diagnosa, krn disitu pun diagnosa ditegakkan setelah si anak ngeliat ciri2 fisik pasiennya..baru ke treatment.
Regards
Laura
Wed Apr 3, 2013 12:41 am (PDT) . Posted by:
"PESAT Balikpapan"
Dear Smart Parents,
Panik setiap kali menghadapi anak sakit? Takut terlambat… takut gagal
tumbuh… dsb, yang selalu membayangi dalam pikiran kita setiap kali anak
sakit.
Atau pernahkan mengalami hal seperti ini:
· Anakku demam. Duuuh… takut kejang, takut infeksi, takut terlambat!
· Anakku batuk pilek gak sembuh-sembuh, obat apa ya yang ampuh?
· Bingung, anakku susah makan, bagaimana nanti kalau kurang gizi?
· Tolong, anakku diare dan muntah-muntah, aku takut ia dehidrasi!
· Sebenernya antibiotic itu musuh atau butuh ya?
…dan seribu satu permasalahan sehari-hari mengenai kesehatan buah hati kita.
Ayah-Bunda tidak perlu panic, semua itu bisa dipelajari lho. Yuk kita
belajar bersama di PESAT (Program Edukasi Kesehatan Anak untuk Orang Tua).
Buat Smart Parents yang tinggal di Balikpapan dan sekitarnya, ada kabar
gembira!!
Kali ini PESAT akan hadir di Balikpapan – Kalimantan Timur.
Hayoo… siapa yang ingin belajar langsung dari narasumbernya? Bertatap muka
langsung dengan dokter-dokter yang terkenal di milis Sehat? Kali ini nggak
usah jauh-jauh menyeberang ke pulau Jawa, tinggal datang saja ke Balikpapan.
Jangan lupa catat ya tanggal mainnya:
*PESAT 1 Balikpapan*
*Tanggal 4 & 5 Mei 2013*
*Pukul 08.00 – 14.30 WITA*
*Tempat di Quartz 2 Room – Panin Tower Lt. 16, Grand Sudirman. Jl. Jend.
Sudirman no. 7, Balikpapan.*
Program ini bekerja sama dengan YOP (Yayasan Orang Tua Peduli), akan
menghadirkan dua pembicara yang ahli dalam bidang kesehatan anak-anak:
*dr. Purnamawati S. Pudjiarto, Sp.Ak, MMPed*
*dr. Endah Citraresmi, SpA*
Pembahasan materi akan dilakukan dalam 2 sesi:
Sesi I, Sabtu 4 Mei 2013
1. Sekarang aku mengerti apa yang harus kulakukan saat anakku batuk,
pilek, radang tenggorokan dan asma.
2. Makanan enak untuk anak.
3. Paradigma "obat dibayarin kantor" jangan membuat kita menjadi
tidak RUM (Rational Use of Medicine)
Sesi II, Minggu 5 Mei 2013
1. Tolong anakku demam! Duuuh… bagaimana kalau kejang? Takut
infeksi.. takut terlambat.
2. Jangan sepelekan diare, muntah dan konstipasi pada anak.
3. Sebenarnya Antibiotik itu butuh atau musuh ya?
Investasi: Rp 125.000,-/orang/sesi
Pendaftaran:
1. Melalu sms ke: 0816-458-4843 (Anti), atau 0812-5469-6979 (Rasma).
Format sms: [nama peserta] [ikut sesi I/sesi II/sesi I & II] [nomor HP yang
bisa dihubungi] atau [alamat email].
2. Melalu email: pesat1balikpapan@gmail.com
Format email:
· Nama peserta
· Ikut sesi I/sesi II/sesi I & II
· Nomor HP yang bisa dihubungi
· Alamat email
Anda akan menerima sms/email dari panitia yang berupa konfirmasi
pendaftaran dan tata cara pembayaran.
Informasi lebih lanjut hubungi:
· Contact person: 0816-458-4843 (Anti), atau 0812-5469-6979 (Rasma).
· Email: pesat1balikpapan@gmail.com
· Website: www.pesatbalikpapan.wordpress.com
· Twitter: @PESATBpn
Ayo segera daftar! Seat terbatas lho… ;)
Salam Sehat!
PESAT Balikpapan – Kalimantan Timur 2013
[Non-text portions of this message have been removed]
Panik setiap kali menghadapi anak sakit? Takut terlambat… takut gagal
tumbuh… dsb, yang selalu membayangi dalam pikiran kita setiap kali anak
sakit.
Atau pernahkan mengalami hal seperti ini:
· Anakku demam. Duuuh… takut kejang, takut infeksi, takut terlambat!
· Anakku batuk pilek gak sembuh-sembuh, obat apa ya yang ampuh?
· Bingung, anakku susah makan, bagaimana nanti kalau kurang gizi?
· Tolong, anakku diare dan muntah-muntah, aku takut ia dehidrasi!
· Sebenernya antibiotic itu musuh atau butuh ya?
…dan seribu satu permasalahan sehari-hari mengenai kesehatan buah hati kita.
Ayah-Bunda tidak perlu panic, semua itu bisa dipelajari lho. Yuk kita
belajar bersama di PESAT (Program Edukasi Kesehatan Anak untuk Orang Tua).
Buat Smart Parents yang tinggal di Balikpapan dan sekitarnya, ada kabar
gembira!!
Kali ini PESAT akan hadir di Balikpapan – Kalimantan Timur.
Hayoo… siapa yang ingin belajar langsung dari narasumbernya? Bertatap muka
langsung dengan dokter-dokter yang terkenal di milis Sehat? Kali ini nggak
usah jauh-jauh menyeberang ke pulau Jawa, tinggal datang saja ke Balikpapan.
Jangan lupa catat ya tanggal mainnya:
*PESAT 1 Balikpapan*
*Tanggal 4 & 5 Mei 2013*
*Pukul 08.00 – 14.30 WITA*
*Tempat di Quartz 2 Room – Panin Tower Lt. 16, Grand Sudirman. Jl. Jend.
Sudirman no. 7, Balikpapan.*
Program ini bekerja sama dengan YOP (Yayasan Orang Tua Peduli), akan
menghadirkan dua pembicara yang ahli dalam bidang kesehatan anak-anak:
*dr. Purnamawati S. Pudjiarto, Sp.Ak, MMPed*
*dr. Endah Citraresmi, SpA*
Pembahasan materi akan dilakukan dalam 2 sesi:
Sesi I, Sabtu 4 Mei 2013
1. Sekarang aku mengerti apa yang harus kulakukan saat anakku batuk,
pilek, radang tenggorokan dan asma.
2. Makanan enak untuk anak.
3. Paradigma "obat dibayarin kantor" jangan membuat kita menjadi
tidak RUM (Rational Use of Medicine)
Sesi II, Minggu 5 Mei 2013
1. Tolong anakku demam! Duuuh… bagaimana kalau kejang? Takut
infeksi.. takut terlambat.
2. Jangan sepelekan diare, muntah dan konstipasi pada anak.
3. Sebenarnya Antibiotik itu butuh atau musuh ya?
Investasi: Rp 125.000,-/orang/
Pendaftaran:
1. Melalu sms ke: 0816-458-4843 (Anti), atau 0812-5469-6979 (Rasma).
Format sms: [nama peserta] [ikut sesi I/sesi II/sesi I & II] [nomor HP yang
bisa dihubungi] atau [alamat email].
2. Melalu email: pesat1balikpapan@
Format email:
· Nama peserta
· Ikut sesi I/sesi II/sesi I & II
· Nomor HP yang bisa dihubungi
· Alamat email
Anda akan menerima sms/email dari panitia yang berupa konfirmasi
pendaftaran dan tata cara pembayaran.
Informasi lebih lanjut hubungi:
· Contact person: 0816-458-4843 (Anti), atau 0812-5469-6979 (Rasma).
· Email: pesat1balikpapan@
· Website: www.pesatbalikpapan
· Twitter: @PESATBpn
Ayo segera daftar! Seat terbatas lho… ;)
Salam Sehat!
PESAT Balikpapan – Kalimantan Timur 2013
[Non-text portions of this message have been removed]
GROUP FOOTER MESSAGE
Milis SEHAT mengucapkan terimakasih kepada:
- Asuransi AIA atas partisipasinya sebagai sponsor PESAT Bali 2011
- PT LG Electronics Indonesia atas partisipasinya sebagai Sponsor Tunggal FAMILY FUN DAY MILIS SEHAT 2011.
Terima kasih & penghargaan sedalam-dalamnya kepada : HBTLaw, PT.Intiland, dan PT. Permata Bank Tbk. yang telah dan konsisten mensponsori program kami, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"Milis SEHAT didukung oleh : CBN Net Internet Access &Website.
=================================================================
Milis Sehat thanks to:
- AIA Insurance as sponsor for PESAT Bali 2011
- PT LG Electronics Indonesia as exclusive partner of FAMILY FUN DAY MILIS SEHAT 2011.
Our biggest gratitude to: HBTLaw, PT. Intiland, and PT. Permata Bank Tbk. who have consistently sponsored our program, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"SEHAT mailing list is supported by CBN Net for Internet Access &Website.
Kunjungi kami di (Visit us at):
Official Web : http://milissehat.web.id/
FB : http://www.facebook.com/pages/Milissehat/131922690207238
Twitter : @milissehat <http://twitter.com/milissehat/>
==================================================================
Donasi (donation):
Rekening Yayasan Orang Tua Peduli
Bank Mandiri
Cabang Kemang Raya Jakarta
Account Number: 126.000.4634514
==================================================================
- Asuransi AIA atas partisipasinya sebagai sponsor PESAT Bali 2011
- PT LG Electronics Indonesia atas partisipasinya sebagai Sponsor Tunggal FAMILY FUN DAY MILIS SEHAT 2011.
Terima kasih & penghargaan sedalam-dalamnya kepada : HBTLaw, PT.Intiland, dan PT. Permata Bank Tbk. yang telah dan konsisten mensponsori program kami, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"Milis SEHAT didukung oleh : CBN Net Internet Access &Website.
=================================================================
Milis Sehat thanks to:
- AIA Insurance as sponsor for PESAT Bali 2011
- PT LG Electronics Indonesia as exclusive partner of FAMILY FUN DAY MILIS SEHAT 2011.
Our biggest gratitude to: HBTLaw, PT. Intiland, and PT. Permata Bank Tbk. who have consistently sponsored our program, PESAT (Program Edukasi Kesehatan Anak Untuk Orang Tua)."
"SEHAT mailing list is supported by CBN Net for Internet Access &Website.
Kunjungi kami di (Visit us at):
Official Web : http://milissehat.web.id/
FB : http://www.facebook.com/pages/Milissehat/131922690207238
Twitter : @milissehat <http://twitter.com/milissehat/>
==================================================================
Donasi (donation):
Rekening Yayasan Orang Tua Peduli
Bank Mandiri
Cabang Kemang Raya Jakarta
Account Number: 126.000.4634514
==================================================================